Leerink Swann reissued their outperform rating on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research report sent to investors on Wednesday, November 15th, The Fly reports. Leerink Swann currently has a $29.00 price objective on the biotechnology company’s stock, up from their prior price objective of $22.00. Leerink Swann also issued estimates for Audentes Therapeutics’ Q4 2017 earnings at ($0.84) EPS, FY2017 earnings at ($3.42) EPS, Q1 2018 earnings at ($0.84) EPS, Q2 2018 earnings at ($0.85) EPS, Q3 2018 earnings at ($0.85) EPS, Q4 2018 earnings at ($0.86) EPS, FY2018 earnings at ($3.40) EPS and FY2019 earnings at ($2.69) EPS.
Several other equities research analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Audentes Therapeutics from a sell rating to a hold rating in a research note on Monday, October 23rd. William Blair assumed coverage on shares of Audentes Therapeutics in a research report on Tuesday, October 17th. They set an outperform rating and a $35.00 price objective for the company. ValuEngine downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a research report on Friday, October 13th. Raymond James Financial assumed coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They set a market perform rating for the company. Finally, Bank of America restated a buy rating and set a $33.00 price objective (up from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Audentes Therapeutics presently has a consensus rating of Hold and an average price target of $27.17.
Shares of Audentes Therapeutics (NASDAQ BOLD) opened at $28.38 on Wednesday. Audentes Therapeutics has a one year low of $13.90 and a one year high of $33.43.
In other news, CEO Matthew R. Patterson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $25.06, for a total transaction of $250,600.00. Following the transaction, the chief executive officer now directly owns 1,542 shares of the company’s stock, valued at $38,642.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Orbimed Advisors Llc sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $22.35, for a total transaction of $111,750.00. The disclosure for this sale can be found here. Insiders have sold 758,500 shares of company stock worth $21,340,610 over the last ninety days. Insiders own 47.30% of the company’s stock.
A number of large investors have recently made changes to their positions in BOLD. Wells Fargo & Company MN increased its stake in Audentes Therapeutics by 278.5% in the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 5,700 shares during the last quarter. SG Americas Securities LLC bought a new position in Audentes Therapeutics in the third quarter valued at approximately $143,000. Nationwide Fund Advisors increased its stake in Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 6,384 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Audentes Therapeutics in the second quarter valued at approximately $210,000. Finally, Rhumbline Advisers bought a new position in Audentes Therapeutics in the second quarter valued at approximately $252,000. 78.99% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Audentes Therapeutics (NASDAQ:BOLD) Stock Rating Reaffirmed by Leerink Swann” was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/04/audentes-therapeutics-inc-bold-earns-outperform-rating-from-leerink-swann.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.